<?xml version="1.0" encoding="UTF-8"?>
<NDC>
<NDCCode>
0338-9581-02
</NDCCode>
<PackageDescription>
1 VIAL, SINGLE-USE in 1 CARTON (0338-9581-02) / 10 mL in 1 VIAL, SINGLE-USE (0338-9581-01)
</PackageDescription>
<NDC11Code>
00338-9581-02
</NDC11Code>
<ProductNDC>
0338-9581
</ProductNDC>
<ProductTypeName>
HUMAN PRESCRIPTION DRUG
</ProductTypeName>
<ProprietaryName>
Doxorubicin Hydrochloride, Liposomal
</ProprietaryName>
<ProprietaryNameSuffix/>
<NonProprietaryName>
Doxorubicin Hydrochloride
</NonProprietaryName>
<DosageFormName>
INJECTION, SUSPENSION, LIPOSOMAL
</DosageFormName>
<RouteName>
INTRAVENOUS
</RouteName>
<StartMarketingDate>
20231219
</StartMarketingDate>
<EndMarketingDate/>
<MarketingCategoryName>
UNAPPROVED DRUG FOR USE IN DRUG SHORTAGE
</MarketingCategoryName>
<ApplicationNumber/>
<LabelerName>
Baxter Healthcare Corporation
</LabelerName>
<SubstanceName>
DOXORUBICIN HYDROCHLORIDE
</SubstanceName>
<StrengthNumber>
2
</StrengthNumber>
<StrengthUnit>
mg/mL
</StrengthUnit>
<Pharm_Classes>
Anthracycline Topoisomerase Inhibitor [EPC], Anthracyclines [CS], Topoisomerase Inhibitors [MoA]
</Pharm_Classes>
<DEASchedule/>
<Status>
Active
</Status>
<LastUpdate>
2025-12-17
</LastUpdate>
<PackageNdcExcludeFlag>
N
</PackageNdcExcludeFlag>
<ProductNdcExcludeFlag>
N
</ProductNdcExcludeFlag>
<ListingRecordCertifiedThrough>
20261231
</ListingRecordCertifiedThrough>
<StartMarketingDatePackage>
20231219
</StartMarketingDatePackage>
<EndMarketingDatePackage/>
<SamplePackage>
N
</SamplePackage>
</NDC>